Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.In order to provide better assistance to its US customers, Estonian biotechnology company Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.
This marks a significant milestone for Icosagen, as well as for the Estonian biotechnology sector in general. Until now, mainly European companies were able to benefit from Icosagen’s unique technologies. The decision to make its IP and services more accessible to US companies has been followed by some customer demand, and it is expected that the US will become the most important foreign market for Icosagen. The commitment to the US market will follow the incremental expansion model, with R&D as well as manufacturing remaining in Estonia during the first phase. However, as the business grows, they will eventually be moved closer to the customers.
Icosagen develops antibodies and manufactures recombinant proteins by using its proprietary technologies. Icosagen’s patented QMCF technology has been successfully licensed to a series of large pharmaceutical and biotechnology companies, and is being used in the development and production of biological therapeutics. The company is ISO 9001:2008 certified, and follows GLP regulations